OPTIMIZATION OF ANTIRESORPTIVE THERAPY WITH BISPHOSPHONATES
- Autores: YURENEVA S.V1, YAKUSHEVSKAYA O.V1
-
Afiliações:
- Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
- Edição: Nº 3 (2011)
- Páginas: 17-22
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246476
- ID: 246476
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
One third of a woman’s life is postmenopausal, i.e. the time of accelerated bone loss, which results in a considerable reduction in bone mineral density and an increase in bone fragility. The first-line drugs for therapy for postmenopausal osteoporosis (PMO) are bisphosphonates (graded validity A). The mean duration of the therapy for PMO is 3 to 5 years. The major problem in treating this disease is low therapy adherence. The design of drugs with the least administrations shows promise for enhancing the adherence to PMO therapy and its effectiveness.
Palavras-chave
Texto integral
Sobre autores
S. YURENEVA
Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
Email: yurenevas@mail.ru
O. YAKUSHEVSKAYA
Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia
Bibliografia
- Аляев Ю.Г., Винаров А.З., Демидко Ю.Л. Обмен кальция, витамина Д3 и мочекаменная болезнь // Клиницист. - 2006. — № 4. - С. 74—76.
- Клинические рекомендации. Остеопороз (диагностика, профилактика и лечение) / Под ред. Л.И. Беневоленской, О.М. Лесняк. — 2-е изд. — М.: «ГЭОТАР-Медиа», 2010.
- American Association of Endocrinologists (AACE) medical guidelines for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 // Endocr. Pract. — 2003. — Vol. 9, № 6. — P. 544—564.
- Brown J.P., Josse R.G. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada // Can. Med. Assoc. J. — 2002. — Vol. 167, № 10, suppl. — Р. S1—S34.
- Green A.D., Colon-Emeric C.S., Bastian L. et al. Does this woman have osteoporosis? // J.A.M.A. — 2004. — Vol. 292, № 23. — P. 2890—2900.
- Institute for Clinical Systems Improvement (ICST) health care guideline: diagnosis and treatment of osteoporosis. — 3rd ed. — July 2004. — www.ICST.org.
- Lyles K.W., Colon-Emeric C.S., Magaziner J.S. Zoledronic acid in reducing clinical fructure and mortality after hip fracture // N. Engl. J. Med. — 2007. — P. 357.
- Marini F., Falchetti A., Silvestri S. et al. Modulatory effect of farnesyl pyrophosphate synthase (FDPS) polymorphism on the response to long-term aminobisphosphonate treatment in postmenopausal osteoporosis. // Curr. Мed. Res. Opin. -2008. — Vol. 24, № 9. - P. 2609—2615.
- Peacock M., Turner C.H., Econs M.J. Genetics of osteoporosis. // Endocr.Rev. - 2001. - Vol. 23. - P. 303—326.
- Reid D., Delmas P. et al. The addition of once-yearly zoledronic acid 5 mg to non-bisphosphonate treatment for osteoporosis reduce fractures in postmenopausal women: The HORIZON PFT // 19th Annual Meeting. — Orlando, 2008. — P. 36.
- Sutton A.L., Mac Donald P.N. Vitamin D: more than a «bone-a-fide» hormone // Mol. Endocrinol. - 2003. — Vol. 17. — Р. 777—791.
Arquivos suplementares
